397 related articles for article (PubMed ID: 20518582)
1. Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.
Plosker GL
Drugs; 2010 Jun; 70(9):1165-88. PubMed ID: 20518582
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on pentavalent rotavirus vaccine (RotaTeq) in the prevention of rotavirus gastroenteritis in Europe.
Plosker GL
BioDrugs; 2010 Dec; 24(6):411-4. PubMed ID: 21043548
[TBL] [Abstract][Full Text] [Related]
3. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.
Ciarlet M; Schödel F
Vaccine; 2009 Dec; 27 Suppl 6():G72-81. PubMed ID: 20006144
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
Vesikari T; Matson DO; Dennehy P; Van Damme P; Santosham M; Rodriguez Z; Dallas MJ; Heyse JF; Goveia MG; Black SB; Shinefield HR; Christie CD; Ylitalo S; Itzler RF; Coia ML; Onorato MT; Adeyi BA; Marshall GS; Gothefors L; Campens D; Karvonen A; Watt JP; O'Brien KL; DiNubile MJ; Clark HF; Boslego JW; Offit PA; Heaton PM;
N Engl J Med; 2006 Jan; 354(1):23-33. PubMed ID: 16394299
[TBL] [Abstract][Full Text] [Related]
5. Rotavirus vaccine (RotaTeq).
Keating GM
Paediatr Drugs; 2006; 8(3):197-202; discussion 203-4. PubMed ID: 16774301
[TBL] [Abstract][Full Text] [Related]
6. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.
Vesikari T; Itzler R; Karvonen A; Korhonen T; Van Damme P; Behre U; Bona G; Gothefors L; Heaton PM; Dallas M; Goveia MG
Vaccine; 2009 Dec; 28(2):345-51. PubMed ID: 19879226
[TBL] [Abstract][Full Text] [Related]
7. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Cortese MM; Parashar UD;
MMWR Recomm Rep; 2009 Feb; 58(RR-2):1-25. PubMed ID: 19194371
[TBL] [Abstract][Full Text] [Related]
8. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine.
Chandran A; Santosham M
Expert Rev Vaccines; 2008 Dec; 7(10):1475-80. PubMed ID: 19053204
[TBL] [Abstract][Full Text] [Related]
9. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5).
Itzler R; Koch G; Matson DO; Gothefors L; Van Damme P; Dinubile MJ; Heaton PM
BMC Pediatr; 2010 Jun; 10():42. PubMed ID: 20540778
[TBL] [Abstract][Full Text] [Related]
10. Update on Rotarix: an oral human rotavirus vaccine.
O'Ryan M; Linhares AC
Expert Rev Vaccines; 2009 Dec; 8(12):1627-41. PubMed ID: 19943758
[TBL] [Abstract][Full Text] [Related]
11. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF
Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138
[TBL] [Abstract][Full Text] [Related]
12. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Parashar UD; Alexander JP; Glass RI;
MMWR Recomm Rep; 2006 Aug; 55(RR-12):1-13. PubMed ID: 16902398
[TBL] [Abstract][Full Text] [Related]
13. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine.
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2007 Jan; 119(1):171-82. PubMed ID: 17200286
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial.
Iwata S; Nakata S; Ukae S; Koizumi Y; Morita Y; Kuroki H; Tanaka Y; Shizuya T; Schödel F; Brown ML; Lawrence J
Hum Vaccin Immunother; 2013 Aug; 9(8):1626-33. PubMed ID: 23732903
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of a rotavirus vaccine into the national immunisation schedule in the United Kingdom: a review.
Nakagomi O; Iturriza-Gomara M; Nakagomi T; Cunliffe NA
Expert Opin Biol Ther; 2013 Nov; 13(11):1613-21. PubMed ID: 24088009
[TBL] [Abstract][Full Text] [Related]
16. Rotavirus live, oral, pentavalent vaccine.
Tom-Revzon C
Clin Ther; 2007 Dec; 29(12):2724-37. PubMed ID: 18201590
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.
Zaman K; Dang DA; Victor JC; Shin S; Yunus M; Dallas MJ; Podder G; Vu DT; Le TP; Luby SP; Le HT; Coia ML; Lewis K; Rivers SB; Sack DA; Schödel F; Steele AD; Neuzil KM; Ciarlet M
Lancet; 2010 Aug; 376(9741):615-23. PubMed ID: 20692031
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.
Armah GE; Sow SO; Breiman RF; Dallas MJ; Tapia MD; Feikin DR; Binka FN; Steele AD; Laserson KF; Ansah NA; Levine MM; Lewis K; Coia ML; Attah-Poku M; Ojwando J; Rivers SB; Victor JC; Nyambane G; Hodgson A; Schödel F; Ciarlet M; Neuzil KM
Lancet; 2010 Aug; 376(9741):606-14. PubMed ID: 20692030
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of an ideal rotavirus vaccine.
Reisinger KS; Block SL
Clin Pediatr (Phila); 2008 Jul; 47(6):555-63. PubMed ID: 18467670
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).
Dennehy PH; Vesikari T; Matson DO; Itzler RF; Dallas MJ; Goveia MG; DiNubile MJ; Heaton PM; Ciarlet M
Hum Vaccin; 2011 May; 7(5):563-8. PubMed ID: 21441783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
